Are you a print subscriber? Activate your account. By Mike Lacey - 1 hour 1 min ago By Tim Nudd - 1 hour 27 min ago By Garett Sloane - 5 hours 15 min ago By Jon Springer - 8 hours 45 min ago 8 ...

There have been calls for caution when it comes to the use of Pfizer’s respiratory syncytial virus (RSV) vaccine in pregnant women, ahead of an FDA advisory committee meeting scheduled to review ...

Add videos to your saved list and come back to them any time.

A nationwide surge in flu, COVID-19, RSV and norovirus infections is fueling concerns of a possible virus "quademic." Or is it just winter? The three respiratory viruses plus norovirus ...

GSK has been the dominant player in the RSV vaccine market since Arexvy first gained approval in 2023, although Pfizer has made inroads into its market share. While initial launches for both ...

AVI Systems, provider of communication and collaboration solution design, integration and support, announced the promotion of five leaders from within the company These promotions emerged as part of ...

GSK has been the dominant player in the RSV vaccine market since Arexvy first gained approval in 2023, although Pfizer has made inroads into its market share. While initial launches for both companies ...

Pfizer expects $1B hit from IRA's Part D redesign and no major M&A in 2025 RSV vaccine Abrysvo specifically ... for profit margin expansion, buoyed by commercial execution and cost-savings efforts ...